文献速递甲状腺疾病

SPRY4 被鉴定为家族性非髓样甲状腺癌的新候选易感基因

Identification of SPRY4 as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer.
PubMed 文献 · Thyroid · 2021-06-03

研究对一个高信息量家族性非髓样甲状腺癌(FNMTC)家系中6名患者的外周血白细胞DNA进行全外显子组测序,筛选并验证共有的致病变异。SPRY4 基因变异 c.701C>T(p.Thr234Met)经体外实验显示可增强细胞活力和集落形成,作用经 MAPK/ERK 通路介导。结果提示 SPRY4 可能是 FNMTC 的新候选易感基因。

要点

  • 对 FNMTC 家系行全外显子组测序可帮助筛选新的易感基因。
  • SPRY4 c.701C>T(p.Thr234Met)在体外赋予甲状腺癌细胞增殖和克隆优势。
  • 该变异的作用经 MAPK/ERK 通路介导,MEK 抑制剂可增强对其的应答。

核心结论

  • 在一个家系中通过全外显子组测序鉴定 SPRY4 为 FNMTC 的可能新候选易感基因。

研究设计与样本

  • 对来自一个高信息量 FNMTC 家系的6名患者白细胞DNA行全外显子组测序,并以 Sanger 测序验证。
  • 通过家系共分离分析、计算机模拟影响评估和数据库基因表达分析筛选最可能致病变异。
  • 对最受关注的 SPRY4 变异进行体外功能实验验证其致病性。

主要发现

  • 在多个候选基因中鉴定出若干可能致病变异,经筛选后优先对 SPRY4 c.701C>T(p.Thr234Met)进行体外功能表征。
  • SPRY4 变异导致细胞活力和集落形成增加,提示其赋予增殖优势和增强克隆形成能力。
  • 磷酸激酶阵列和 Western blot 分析提示该变异效应经 MAPK/ERK 通路介导。
  • 携带 SPRY4 变异的甲状腺癌细胞对 MEK 抑制剂反应性更高,进一步支持 MAPK/ERK 通路介导。

临床怎么用

  • 对 FNMTC 家系可考虑全外显子组测序以发现候选易感基因,辅助分子诊断和临床管理。
  • SPRY4 变异携带状态或可提示甲状腺癌细胞对 MEK 抑制剂的敏感性,但需进一步临床验证。

局限性

  • 研究仅基于一个家系,SPRY4 作为 FNMTC 易感基因的证据尚需更多家系和人群验证。
  • 功能验证主要来自体外实验,缺乏体内模型和临床队列数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The molecular basis of familial nonmedullary thyroid cancer (FNMTC) is still poorly understood, representing a limitation for molecular diagnosis and clinical management. In this study, we aimed to identify new susceptibility genes for FNMTC through whole-exome sequencing (WES) analysis of leukocyte DNA of patients from a highly informative FNMTC family. Methods: We selected six affected family members to conduct WES analysis. Bioinformatic analyses were undertaken to filter and select the genetic variants shared by the affected members, which were subsequently validated by Sanger sequencing. To select the most likely pathogenic variants, several studies were performed, including family segregation analysis, in silico impact characterization, and gene expression (messenger RNA and protein) depiction in databases. For the most promising variant identified, we performed in vitro studies to validate its pathogenicity. Results: Several potentially pathogenic variants were identified in different candidate genes. After filtering with appropriate criteria, the variant c.701C>T, p.Thr234Met in the SPRY4 gene was prioritized for in vitro functional characterization. This SPRY4 variant led to an increase in cell viability and colony formation, indicating that it confers a proliferative advantage and potentiates clonogenic capacity. Phosphokinase array and Western blot analyses suggested that the effects of the SPRY4 variant were mediated through the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway, which was further supported by a higher responsiveness of thyroid cancer cells with the SPRY4 variant to a MEK inhibitor. Conclusions: WES analysis in one family identified SPRY4 as a likely novel candidate susceptibility gene for FNMTC, allowing a better understanding of the cellular and molecular mechanisms underlying thyroid cancer development.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Marques IJ, Gomes I, Pojo M, et al. Identification of SPRY4 as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer. Thyroid. 2021. PMID: 33906393. doi:10.1089/thy.2020.0290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。